Payment overview · 2025
General Payments
$1,036.01
58 reported records · 18 companies
Healthcare provider profile · identity verified
Lee Carter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AUTAUGAVILLE, AL · NPI 1437365012
Verified facts
What the public records show
CMS Open Payments records show Lee Carter, M.D. received $1,036.01 in general payments during 2025 across 58 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nuplazid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 532 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $226.15 | 21.8% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.41 | 17.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.17 | 8.9% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $75.50 | 7.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.98 | 7.2% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $65.11 | 6.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.38 | 6.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $41.58 | 4.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.40 | 2.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.08 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.52 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.25 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.52 | 2.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.61 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.40 | 1.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.26 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.93 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.76 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,036.01 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $226.15 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.98 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $75.50 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $74.98 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.79 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.79 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $65.11 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $60.67 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.85 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.96 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $41.58 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.20 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.40 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.08 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 532 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 264 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 199 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 285 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 188 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
181 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
532 | 111 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
264 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
188 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
264 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
199 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
320 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
285 | 58 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1950 | 256 |
| Gabapentin | Gabapentin | 1171 | 205 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1040 | 250 |
| Amlodipine Besylate | Amlodipine Besylate | 859 | 228 |
| Levothyroxine Sodium | Levothyroxine Sodium | 836 | 185 |
| Pantoprazole Sodium | Pantoprazole Sodium | 829 | 210 |
| Losartan Potassium | Losartan Potassium | 717 | 206 |
| Furosemide | Furosemide | 663 | 182 |
| Eliquis | Apixaban | 620 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 615 | 164 |
| Montelukast Sodium | Montelukast Sodium | 610 | 170 |
| Trazodone Hcl | Trazodone Hcl | 596 | 130 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 547 | 143 |
| Carvedilol | Carvedilol | 537 | 140 |
| Farxiga | Dapagliflozin Propanediol | 532 | 111 |
| Potassium Chloride | Potassium Chloride | 509 | 131 |
| Prednisone | Prednisone | 476 | 229 |
| Lorazepam | Lorazepam | 443 | 86 |
| Metformin Hcl | Metformin Hcl | 437 | 113 |
| Omeprazole | Omeprazole | 425 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 399 | 102 |
| Buspirone Hcl | Buspirone Hcl | 398 | 85 |
| Methocarbamol | Methocarbamol | 380 | 94 |
| Famotidine | Famotidine | 348 | 81 |
| Lisinopril | Lisinopril | 343 | 102 |
| Pregabalin | Pregabalin | 332 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 322 | 201 |
| Trulicity | Dulaglutide | 320 | 61 |
| Azithromycin | Azithromycin | 306 | 197 |
| Metoprolol Tartrate | Metoprolol Tartrate | 302 | 79 |
| Meloxicam | Meloxicam | 288 | 76 |
| Tramadol Hcl | Tramadol Hcl | 286 | 79 |
| Ozempic | Semaglutide | 285 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 280 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 278 | 60 |
| Donepezil Hcl | Donepezil Hcl | 274 | 57 |
| Jardiance | Empagliflozin | 264 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 263 | 64 |
| Cefdinir | Cefdinir | 250 | 154 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 239 | 46 |
| Sertraline Hcl | Sertraline Hcl | 232 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 231 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 224 | 69 |
| Simvastatin | Simvastatin | 220 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 217 | 52 |
| Mirtazapine | Mirtazapine | 215 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 199 | 41 |
| Mounjaro | Tirzepatide | 199 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 193 | 44 |
| Ondansetron Odt | Ondansetron | 188 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 188 | 45 |
| Linzess | Linaclotide | 181 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 54 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 173 | 81 |
| Celecoxib | Celecoxib | 172 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 45 |
| Ezetimibe | Ezetimibe | 170 | 39 |
| Amoxicillin | Amoxicillin | 157 | 89 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 155 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 58 |
| Memantine Hcl | Memantine Hcl | 153 | 31 |
| Diazepam | Diazepam | 149 | 22 |
| Allopurinol | Allopurinol | 145 | 31 |
| Levetiracetam | Levetiracetam | 139 | 25 |
| Divalproex Sodium | Divalproex Sodium | 135 | 28 |
| Fluconazole | Fluconazole | 130 | 75 |
| Spironolactone | Spironolactone | 128 | 34 |
| Vascepa | Icosapent Ethyl | 124 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 123 | 33 |
| Tradjenta | Linagliptin | 123 | 14 |
| Meclizine Hcl | Meclizine Hcl | 122 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 121 | 46 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 118 | 33 |
| Ibuprofen | Ibuprofen | 116 | 28 |
| Glimepiride | Glimepiride | 115 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 113 | 42 |
| Sucralfate | Sucralfate | 112 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 111 | 32 |
| Nystatin | Nystatin | 110 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 23 |
| Atenolol | Atenolol | 106 | 23 |
| Baclofen | Baclofen | 106 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 42 |
| Warfarin Sodium | Warfarin Sodium | 103 | 12 |
| Bumetanide | Bumetanide | 101 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 101 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 61 |
| Clonidine Hcl | Clonidine Hcl | 99 | 31 |
| Entresto | Sacubitril/Valsartan | 99 | 19 |
| Levofloxacin | Levofloxacin | 98 | 68 |
| Mupirocin | Mupirocin | 98 | 64 |
| Ramipril | Ramipril | 86 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 84 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 81 | 49 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 21 |
| Xarelto | Rivaroxaban | 80 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 79 | 25 |
| Clonazepam | Clonazepam | 78 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 54 |
| Colchicine | Colchicine | 74 | 20 |
| Alendronate Sodium | Alendronate Sodium | 72 | 22 |
| Januvia | Sitagliptin Phosphate | 71 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 70 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 29 |
| Bupropion Xl | Bupropion Hcl | 66 | 12 |
| Myrbetriq | Mirabegron | 66 | 16 |
| Finasteride | Finasteride | 62 | 17 |
| Aripiprazole | Aripiprazole | 59 | 13 |
| Doxepin Hcl | Doxepin Hcl | 58 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 58 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 53 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 53 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 51 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 15 |
| Klor-Con 10 | Potassium Chloride | 48 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Olanzapine | Olanzapine | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 13 |
| Lactulose | Lactulose | 43 | 17 |
| Methimazole | Methimazole | 43 | 11 |
| Insulin Lispro | Insulin Lispro | 41 | 11 |
| Lacosamide | Lacosamide | 41 | suppressed |
| Telmisartan | Telmisartan | 39 | 13 |
| Novolog | Insulin Aspart | 38 | 16 |
| Ofloxacin | Ofloxacin | 38 | 24 |
| Ranolazine Er | Ranolazine | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 30 |
| Risperidone | Risperidone | 37 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | 11 |
| Nuplazid | Pimavanserin Tartrate | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Humalog | Insulin Lispro | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 11 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Erythromycin | Erythromycin Base | 32 | 28 |
| Phenobarbital | Phenobarbital | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | 13 |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 14 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Metronidazole | Metronidazole | 30 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 21 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 15 |
| Lidocaine | Lidocaine | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Premarin | Estrogens, Conjugated | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | 11 |
| Glipizide | Glipizide | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | 20 |
| Haloperidol | Haloperidol | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Levetiracetam Er | Levetiracetam | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Levemir | Insulin Detemir | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 20 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Xtandi | Enzalutamide | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Trulance | Plecanatide | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | 14 |
| Ssd | Silver Sulfadiazine | 16 | 12 |
| Temazepam | Temazepam | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Acetazolamide Er | Acetazolamide | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Klor-Con M15 | Potassium Chloride | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,036.01 · 58 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, DAYBUE, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, INGREZZA, JARDIANCE, Jornay PM, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error